Context
How does CBD compare to other arthritis treatments?
TL;DR — What the Evidence Shows
Several arthritis treatments have strong evidence. Physical therapy and topical NSAIDs are well-studied and widely recommended.
CBD has very low certainty evidence for arthritis pain. All treatments have trade-offs.
How does the evidence compare?
This table compares treatments that have been studied for osteoarthritis pain. Evidence certainty ratings follow the GRADE framework and rate a specific outcome, not the treatment overall.
| Treatment | Evidence certainty | Key findings | Monthly cost | Insurance |
|---|---|---|---|---|
| Physical therapy / exercise | Moderate Certainty | Pain improvement of 9–13 points on a 0–100 scale vs. no treatment (Cochrane 2024) (139 trials, 12,468 participants). Unanimously recommended as first-line treatment. | $20–$50 copay | Usually covered |
| Topical NSAIDs (diclofenac gel) | High Certainty | Similar effectiveness to oral NSAIDs for knee osteoarthritis with about 38 out of 100 fewer adverse events (da Costa et al. 2021 (da Costa 2021); 122 randomized controlled trials). ACR 2019 strongly recommends for knee osteoarthritis. | $15–$50 | Often covered |
| Oral NSAIDs (ibuprofen, naproxen) | High Certainty | Moderate pain relief. FDA black box warning: risk of heart attack or stroke can occur in the first weeks of use. About 13–15 out of 100 users experience upper GI adverse effects. | $5–$74 | Usually covered |
| Duloxetine (Cymbalta) | Moderate Certainty | FDA-approved for osteoarthritis pain. Moderate effect in trials. Common side effects include nausea, fatigue, and constipation. Withdrawal symptoms possible with abrupt discontinuation. | $4–$25 | Usually covered |
| Acetaminophen (Tylenol) | High Certainty | High certainty that it does not work well for osteoarthritis. About 4 points improvement on a 0–100 pain scale—below the threshold most researchers consider noticeable (Machado et al. 2015 (Machado 2015); 13 randomized controlled trials, 5,366 participants). | $5–$15 | HSA/FSA eligible |
| Corticosteroid injections | Moderate Certainty | Clinically meaningful pain reduction for up to 6 weeks only. No benefit demonstrated beyond 6 weeks. May accelerate cartilage loss (McAlindon 2017). | $20–$300 | Often covered |
| Hyaluronic acid injections | Low Certainty | Controversial. Most reviews find statistically significant effects, but clinical relevance is debated. ACR 2019 conditionally recommends against. Guidelines sharply diverge. | $1,200–$3,000/series | Sometimes covered |
| Joint replacement | High Certainty | Highly effective for end-stage osteoarthritis. More than 90 out of 100 implants function at 10 years. Major surgery with real risks: infection (about 2 out of 100), blood clots, implant failure. | $50K–$150K | Covered |
| CBD (oral) | Very Low Certainty | No benefit over placebo in osteoarthritis-specific trials. Three trials (Vela 2022 (Vela 2022), Bialas 2023 (Bialas 2023), CANOA 2025 (Mojoli 2025)) all found no significant difference from placebo. ACP 2025 (ACP 2025): "Known harms may outweigh potentially small degree of benefit." | $38–$150+ | Never covered |
Evidence certainty follows GRADE methodology. Monthly costs are typical US out-of-pocket estimates. Sources: (Kolasinski 2020) (da Costa 2021) (Machado 2015) (Cochrane 2024)
Do conventional treatments have problems too?
Yes. Equal scrutiny matters. Conventional treatments have real limitations:
- Acetaminophen likely does not work for osteoarthritis. Despite being the most widely used osteoarthritis pain medication, it provides only about 4 points of pain improvement on a 100-point scale. That is below the threshold most researchers consider a noticeable difference. The ACR only conditionally recommends it when alternatives are not tolerated.
- Oral NSAIDs carry cardiovascular risks. The FDA requires a black box warning on all prescription NSAIDs: the risk of heart attack or stroke can occur as early as the first weeks of use. All guidelines emphasize the lowest dose for the shortest duration.
- Corticosteroid injections may damage cartilage. A two-year trial found greater cartilage volume loss with quarterly injections vs. saline (McAlindon 2017). A 2025 Radiology study found structural damage even after a single injection. Benefits last only about 6 weeks.
- Hyaluronic acid injections are controversial. The ACR conditionally recommends against them, yet some guidelines recommend them. They cost $1,200 to $3,000 per series without insurance.
"Standard treatment" is not the same as "highly effective treatment." The comparison to CBD is about evidence certainty, not a claim that conventional options are perfect.
What do the guidelines recommend first?
The American College of Rheumatology (ACR) 2019 guidelines (Kolasinski 2020) for knee, hip, and hand osteoarthritis distinguish between strong and conditional recommendations:
Strongly recommended
- Exercise and physical therapy
- Weight management (for patients who are overweight)
- Topical NSAIDs (for knee osteoarthritis)
Conditionally recommended
- Oral NSAIDs (lowest dose, shortest duration)
- Duloxetine
- Corticosteroid injections
CBD is not addressed in the ACR 2019 guidelines. The American College of Physicians stated in 2025 (ACP 2025) that for chronic pain broadly, "known harms may outweigh potentially small degree of benefit" for cannabinoids.
CBD interacts with many common medications
- Blood thinners (warfarin): CBD can increase bleeding risk by raising INR levels
- Statins, blood pressure medications, and immunosuppressants may also be affected
- CBD inhibits the same liver enzymes that process many prescription drugs
Based on cited sources. This is not personalized medical advice — discuss with your healthcare provider.
Full drug interaction guide, medication checker, and pharmacist discussion checklist.
Key sources cited on this page
Page last reviewed: March 2026 · Authored by Claude (Anthropic AI) · Research methodology